Modi’in Technology Park
2 HaMa’ayan Street
Hevel Modi'in 7177871
Israel
972 8 642 9100
https://www.biolinerx.com
Sector(s): Healthcare
Industry: Biotechnology
Full Time Employees: 79
Name | Title | Pay | Exercised | Year Born |
---|---|---|---|---|
Mr. Philip A. Serlin CPA, M.B.A., CPA, MBA | Chief Executive Officer | 598k | N/A | 1960 |
Ms. Mali Zeevi CPA, CPA | Chief Financial Officer | 374k | N/A | 1976 |
Dr. Ella Sorani Ph.D. | Chief Development Officer | 452k | N/A | 1968 |
Ms. Holly W. May M.B.A. | President of BioLineRx USA | 710k | N/A | 1962 |
Mr. John Lacey | Head of Corporate Communications & Investor Relations | N/A | N/A | N/A |
Ms. Tsipi Keren-Lehrer B.Sc., L.L.B. | Head of BD & Strategic Advisor | N/A | N/A | N/A |
Mr. Raziel Fried | Treasurer & Budgetary Control Director | N/A | N/A | N/A |
BioLineRx Ltd., a pre-commercial-stage biopharmaceutical company, focuses on oncology. The company develops Motixafortide, a peptide, which has completed Phase 3 clinical trials for the treatment of autologous stem cell mobilization and Phase 2a clinical trials for the treatment of pancreatic cancer; and that is in Phase 2 clinical trials for the treatment of metastatic pancreatic adenocarcinoma patients, and Phase 1b clinical trials in patients with acute respiratory distress syndrome secondary to COVID-19 and other respiratory viral infections, as well as for the treatment of solid tumors and acute myeloid leukemia. It is also developing AGI-134, an immuno-oncology agent, which is in Phase 1/2a clinical trials for the treatment of solid tumors; and BL-5010, a customized, proprietary, pen-like applicator for the non-surgical removal of skin lesions. The company has collaboration agreement with MSD for the cancer immunotherapy field; and MD Anderson Cancer Center to investigate the combination of Motixafortide with KEYTRUDA (pembrolizumab) in pancreatic cancer, as well as licensing arrangement with Perrigo Company plc for over-the-counter sale of BL-5010. BioLineRx Ltd. was incorporated in 2003 and is headquartered in Modi'in, Israel.
BioLineRx Ltd.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.